Inpixon Prices $9 Million Public Offering in an Effort to Satisfy Nasdaq’s Stockholders’ Equity Requirement
NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor